Qurient Co. Ltd (115180) - Total Liabilities
Based on the latest financial reports, Qurient Co. Ltd (115180) has total liabilities worth ₩6.81 Billion KRW (≈ $4.61 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Qurient Co. Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how Qurient Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See 115180 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Qurient Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Qurient Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pharmicell
KO:005690
|
Korea | ₩19.60 Billion |
|
Qingdao Copton Technology Co Ltd
SHG:603798
|
China | CN¥169.56 Million |
|
Zhejiang Jihua Group Co Ltd
SHG:603980
|
China | CN¥590.92 Million |
|
Shenzhen King Brother Electronics Technology Co.Ltd.
SHE:301041
|
China | CN¥259.98 Million |
|
Dexterra Group Inc
TO:DXT
|
Canada | CA$467.63 Million |
|
Aprogen KIC Inc
KO:007460
|
Korea | ₩323.51 Billion |
|
Brainsway Ltd
NASDAQ:BWAY
|
USA | $41.20 Million |
|
Beijing Beetech Inc
SHE:300667
|
China | CN¥341.40 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Qurient Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Qurient Co. Ltd market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Qurient Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Qurient Co. Ltd (2014–2024)
The table below shows the annual total liabilities of Qurient Co. Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩7.97 Billion ≈ $5.40 Million |
+35.53% |
| 2023-12-31 | ₩5.88 Billion ≈ $3.99 Million |
+79.65% |
| 2022-12-31 | ₩3.28 Billion ≈ $2.22 Million |
-7.61% |
| 2021-12-31 | ₩3.55 Billion ≈ $2.40 Million |
-16.46% |
| 2020-12-31 | ₩4.24 Billion ≈ $2.88 Million |
+35.36% |
| 2019-12-31 | ₩3.14 Billion ≈ $2.12 Million |
-17.30% |
| 2018-12-31 | ₩3.79 Billion ≈ $2.57 Million |
+230.89% |
| 2017-12-31 | ₩1.15 Billion ≈ $776.40K |
-39.40% |
| 2016-12-31 | ₩1.89 Billion ≈ $1.28 Million |
+96.17% |
| 2015-12-31 | ₩963.76 Million ≈ $653.12K |
-97.09% |
| 2014-12-31 | ₩33.11 Billion ≈ $22.44 Million |
-- |
About Qurient Co. Ltd
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as … Read more